Stocks
ADC Therapeutics SAADCT
NYSEHealthcareBiotechnology$1.58
Price as of · delayed, not real-time
A commercial-stage biopharmaceutical company developing antibody drug conjugates (ADCs) for hematologic malignancies and solid tumors. Its lead product, Zynlonta, is approved for relapsed or refractory large B-cell lymphoma, and the pipeline includes multiple early-stage ADC candidates. Investors track the company for its targeted cancer therapy platform and clinical data readouts.
52W Range: $0.78-$4.98
Congressional Interest in ADC Therapeutics SA (ADCT)
2 members of Congress have disclosed 6 trades in ADC Therapeutics SA (ADCT), a Healthcare company. The buy/sell breakdown shows 2 purchases versus 4 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
6
Unique Politicians
2
Buys
2
Sells
4
Who in Congress Is Trading ADCT?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2025-02-20 | Ashley Moody | sell | $1K-$15K |
| 2010-09-06 | MICHAEL T. MCCAUL | buy | $1K-$15K |
| 2010-05-05 | MICHAEL T. MCCAUL | sell | $1K-$15K |
| 2010-05-03 | MICHAEL T. MCCAUL | buy | $1K-$15K |
| 2010-03-06 | MICHAEL T. MCCAUL | sell | $1K-$15K |
| 2010-01-06 | MICHAEL T. MCCAUL | sell | $1K-$15K |